Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent Temozolomide
ABSTRACT Introduction With the use of immune checkpoint inhibitors (ICIs) and targeted therapies, the clinical outcomes of metastatic melanoma have drastically improved. The current scenario has reduced the use of chemotherapy as a first‐line treatment. We report an interesting case of a patient wit...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.70121 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832577743304261632 |
|---|---|
| author | Anusha Mruthyunjaya Swamy Deepak Sundriyal Mayank Kapoor Mridul Khanna Ravi Hari Phulware Kranthi Kumar Jandrasupalli Ujjawal Shriwastav Amit Sehrawat |
| author_facet | Anusha Mruthyunjaya Swamy Deepak Sundriyal Mayank Kapoor Mridul Khanna Ravi Hari Phulware Kranthi Kumar Jandrasupalli Ujjawal Shriwastav Amit Sehrawat |
| author_sort | Anusha Mruthyunjaya Swamy |
| collection | DOAJ |
| description | ABSTRACT Introduction With the use of immune checkpoint inhibitors (ICIs) and targeted therapies, the clinical outcomes of metastatic melanoma have drastically improved. The current scenario has reduced the use of chemotherapy as a first‐line treatment. We report an interesting case of a patient with stage IV ano‐rectal canal malignant melanoma with an exceptional response to single‐agent temozolomide. Case Report We diagnosed a 55‐year‐old female with stage IV anorectal melanoma, BRAF V600 mutation negative. Owing to her poor performance status (PS) and non‐affordability of immunotherapy, after informed decision‐making, she was started on single agent, temozolomide. She achieved a complete metabolic response and sustained it for 3 years and continues to do so with the first‐line single‐agent temozolomide. Conclusion In a resource‐limited setting, where access to ICIs and targeted therapies is not feasible, and in patients who fail to tolerate these therapies, oral chemotherapy continues to remain effective and is worth trying in patients with poor PS. |
| format | Article |
| id | doaj-art-64ff4d32227842c0a8b7ba49dd3a9a09 |
| institution | Kabale University |
| issn | 2573-8348 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj-art-64ff4d32227842c0a8b7ba49dd3a9a092025-01-30T15:46:35ZengWileyCancer Reports2573-83482025-01-0181n/an/a10.1002/cnr2.70121Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent TemozolomideAnusha Mruthyunjaya Swamy0Deepak Sundriyal1Mayank Kapoor2Mridul Khanna3Ravi Hari Phulware4Kranthi Kumar Jandrasupalli5Ujjawal Shriwastav6Amit Sehrawat7Department of Medical Oncology, Hematology All India Institute of Medical Sciences Rishikesh Uttarakhand IndiaDepartment of Medical Oncology, Hematology All India Institute of Medical Sciences Rishikesh Uttarakhand IndiaDepartment of Medical Oncology, Hematology All India Institute of Medical Sciences Rishikesh Uttarakhand IndiaDepartment of Medical Oncology, Hematology All India Institute of Medical Sciences Rishikesh Uttarakhand IndiaDepartment of Pathology and Laboratory Medicine All India Institute of Medical Sciences Rishikesh Uttarakhand IndiaDepartment of Pathology and Laboratory Medicine All India Institute of Medical Sciences Rishikesh Uttarakhand IndiaAll India Institute of Medical Sciences Rishikesh Uttarakhand IndiaDepartment of Medical Oncology, Hematology All India Institute of Medical Sciences Rishikesh Uttarakhand IndiaABSTRACT Introduction With the use of immune checkpoint inhibitors (ICIs) and targeted therapies, the clinical outcomes of metastatic melanoma have drastically improved. The current scenario has reduced the use of chemotherapy as a first‐line treatment. We report an interesting case of a patient with stage IV ano‐rectal canal malignant melanoma with an exceptional response to single‐agent temozolomide. Case Report We diagnosed a 55‐year‐old female with stage IV anorectal melanoma, BRAF V600 mutation negative. Owing to her poor performance status (PS) and non‐affordability of immunotherapy, after informed decision‐making, she was started on single agent, temozolomide. She achieved a complete metabolic response and sustained it for 3 years and continues to do so with the first‐line single‐agent temozolomide. Conclusion In a resource‐limited setting, where access to ICIs and targeted therapies is not feasible, and in patients who fail to tolerate these therapies, oral chemotherapy continues to remain effective and is worth trying in patients with poor PS.https://doi.org/10.1002/cnr2.70121ano‐rectal melanomachemotherapycomplete metabolic responsetemozolomide |
| spellingShingle | Anusha Mruthyunjaya Swamy Deepak Sundriyal Mayank Kapoor Mridul Khanna Ravi Hari Phulware Kranthi Kumar Jandrasupalli Ujjawal Shriwastav Amit Sehrawat Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent Temozolomide Cancer Reports ano‐rectal melanoma chemotherapy complete metabolic response temozolomide |
| title | Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent Temozolomide |
| title_full | Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent Temozolomide |
| title_fullStr | Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent Temozolomide |
| title_full_unstemmed | Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent Temozolomide |
| title_short | Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent Temozolomide |
| title_sort | prolonged remission in metastatic ano rectal malignant melanoma with single agent temozolomide |
| topic | ano‐rectal melanoma chemotherapy complete metabolic response temozolomide |
| url | https://doi.org/10.1002/cnr2.70121 |
| work_keys_str_mv | AT anushamruthyunjayaswamy prolongedremissioninmetastaticanorectalmalignantmelanomawithsingleagenttemozolomide AT deepaksundriyal prolongedremissioninmetastaticanorectalmalignantmelanomawithsingleagenttemozolomide AT mayankkapoor prolongedremissioninmetastaticanorectalmalignantmelanomawithsingleagenttemozolomide AT mridulkhanna prolongedremissioninmetastaticanorectalmalignantmelanomawithsingleagenttemozolomide AT ravihariphulware prolongedremissioninmetastaticanorectalmalignantmelanomawithsingleagenttemozolomide AT kranthikumarjandrasupalli prolongedremissioninmetastaticanorectalmalignantmelanomawithsingleagenttemozolomide AT ujjawalshriwastav prolongedremissioninmetastaticanorectalmalignantmelanomawithsingleagenttemozolomide AT amitsehrawat prolongedremissioninmetastaticanorectalmalignantmelanomawithsingleagenttemozolomide |